Format

Send to

Choose Destination
Clin Cancer Res. 2017 May 15;23(10):2405-2413. doi: 10.1158/1078-0432.CCR-16-1789. Epub 2016 Nov 7.

A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma.

Author information

1
Department of Medicine, The University of Hong Kong, Hong Kong, China.
2
Division of Diagnostic Imaging and Intervention, University of Pisa, Pisa, Italy.
3
Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
4
Cancer Center, Taipei Veterans General Hospital, Taipei, Taiwan.
5
Internal Medicine, National Cheng University Hospital, Tainan, Taiwan.
6
Clinical Cancer Research Center, National Cancer Institute of Thailand, Bangkok, Thailand.
7
Graduate Institute of Clinical Medicine, National Taiwan University Hospital, Taipei, Taiwan.
8
Division of Digestive and Liver Diseases, Phramongkutklao Hospital, Bangkok, Thailand.
9
PPD, Inc., Austin, Texas.
10
GlaxoSmithKline, King of Prussia, Pennsylvania.
11
GlaxoSmithKline, Collegeville, Pennsylvania.
12
Urologic Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland.
13
GlaxoSmithKline, Uxbridge, United Kingdom.
14
Department of Surgery, The University of Hong Kong, Hong Kong, China.
15
Urologic Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland. dbottaro@helix.nih.gov.

Abstract

Purpose: This phase I/II single-arm study evaluated the safety, pharmacokinetics, pharmacodynamics, and activity of foretinib, an oral multikinase inhibitor of MET, ROS, RON, AXL, TIE-2, and VEGFR2, in the first-line setting in advanced hepatocellular carcinoma patients.Experimental Design: In the phase I part, advanced hepatocellular carcinoma patients were dose escalated on foretinib (30-60 mg) every day using the standard 3+3 design. Once the maximum tolerated dose (MTD) was determined, an additional 32 patients were dosed at the MTD in the phase II expansion cohort for assessment of efficacy and safety. Exploratory analyses were conducted to assess potential biomarkers that might correlate with clinical efficacy and survival.Results: The MTD of foretinib was established as 30 mg every day. The most frequent adverse events were hypertension, decreased appetite, ascites, and pyrexia. When dosed at 30 mg every day in the first-line setting, foretinib demonstrated promising antitumor activity. According to the modified mRECIST, the objective response rate was 22.9%, the disease stabilization rate 82.9%, and the median duration of response 7.6 months. The median time to progression was 4.2 months and the median overall survival (OS) was 15.7 months. Fifteen candidate biomarkers whose levels in the circulation were significantly altered in response to foretinib treatment were elucidated. Multivariate analyses identified IL6 and IL8 as independent predictors of OS.Conclusions: Foretinib demonstrated promising antitumor activity and good tolerability in the first-line setting in Asian advanced hepatocellular carcinoma patients. Baseline plasma levels of IL6 or IL8 might predict the response to foretinib. Clin Cancer Res; 23(10); 2405-13. ©2016 AACR.

PMID:
27821605
PMCID:
PMC5420486
DOI:
10.1158/1078-0432.CCR-16-1789
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center